Previous 10 | Next 10 |
2023-11-14 16:08:08 ET More on Capricor Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Capricor Therapeutics Q3 2023 Earnings Preview Capricor Therapeutics Q3 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Capricor Therapeutics Inc. (CAPR) is expected to report $-0.27 for Q3 2023
2023-11-13 17:35:40 ET More on Capricor Therapeutics Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch ...
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial result...
Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - Caprock Mining Corp. (CSE:CAPR) (" Caprock " or the " Company ") is pleased to announce the results of a high-resolution, drone-based magnetics survey that was recently completed at its Ackley Lithium-Tin-Molybdenum-REEs property (" Ackley "...
Toronto, Ontario--(Newsfile Corp. - November 1, 2023) - Caprock Mining Corp. (CSE: CAPR) (" Caprock " or the " Company ") is pleased to announce that Mr. Jim Kirke has joined the Company's Board of Directors, effective immediately. Mr. Kirke is a Canadian Chartered Professional Accountant with o...
2023-10-25 12:39:22 ET Summary Recent dip in CAPR's stock price following update on regulatory pathway for CAP-1002 and cash raise represents a buying opportunity. Completion of enrollment of Cohort A of ongoing Phase 3 trial of CAP-1002 is expected in Q4 2023, topline results in ...
SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company ...
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of Exosome-Based Delivery of ASOs- SAN DIEGO, Oct. 10, 2023 (GLOB...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...